Presumably this pattern of gemcitabine sensitivity is directly relevant to the cytotoxic anti-neoplatic potency detected for gemcibatine-(C4-amide)-[anti-HER2/neu] in chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) populations (Figure 4). Here, ERBB2 is linked to breast adenocarcinoma.